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A cationic dendritic polyfluorene (PFP) is examined as a siRNA delivery vector. This material was designed to facilitate the nu-
cleic acid binding, encapsulation and efficient cellular uptake. PFP can effectively protect siRNA against nuclease degradation, 
which is necessary for gene carriers. PFP can be used for multidrug resistance gene-targeted siRNA delivery in doxorubicin 
(Dox)-resistant human breast cancer cells (MCF7) cells. As a siRNA transfection agent, PFP can efficiently achieve the reversal 
of drug resistance and enhance the drug sensitivity. These new features and capabilities represent a major step toward conjugated 
polymers that can function for therapeutic application. 
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Breast carcinoma has become the main killer among women 
worldwide [1]. Particularly, multidrug resistance (MDR) 
has been a major obstacle to the successful chemotherapy of 
progressive breast cancer [2]. The overexpression of MDR1 
gene and its product, P-glycoprotein (P-gp), is the major 
mechanism causing the drug resistance. P-gp acts as an  
energy-dependent drug efflux pump to extrude chemother-
apeutic drugs such as doxorubicin (Dox) from cell cyto-
plasm to outside of plasma membrane [3], leading to re-
duced intracellular effective drug concentration and aug-
menting cell survival. A lot of research has done to reverse 
MDR, for example, several compounds which can inhibit 
the efflux activity of drug transporters have been fully in-
vestigated for sensitizing cancer cells to chemotherapy, but 
their clinical application is still limited because of serious 
side effects [4,5]. Therefore, new strategies which can 
down-regulating the drug resistance should be developed. 
Gene-based therapies hold great potential in pharmaceu-
tical research [6,7]. Specially, small interfering RNAs 
(siRNA) are widely employed to achieve effective gene 
regulation [8,9]. Despite the considerable potential of  
siRNA for treating cancers, it is generally recognized that 
the main obstacle to the use of siRNA therapeutics is inad-
equate delivery and transfection. The cellular uptake of na-
ked siRNA would be very low because of the molecules’ 
negative charge renders them poor membrane permeability. 
In addition, the rapid degradation of nucleic acids, particu-
larly siRNA by serum nucleases is really a big problem that 
further aggravates the need for a protective carrier [10]. 
Many promising strategies have been developed for plasmid 
DNA (pDNA) and siRNA delivery. Recombinant viruses 
are proved to be effective transfection vectors, however, 
serious problems of immunogenicity, carcinogenicity and 
inflammation hinder their further clinical application [11]. 
Thus the development of nonviral vectors is of particular 
important in recent years, such as cationic polymers and 
lipids. However, their delivery efficiency remains low [12]. 
Therefore, developing new safe and efficient transfection 
agents is still required. 
Very recently, conjugated polymers have been demon-
strated for sensing and biomedical applications because of 
their high fluorescence brightness, good photostability, and 
lower toxicity [1322]. We have developed an intrinsically 
fluorescent cationic polyfluorene [23] (PFP, see its chemcial 
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structure in Scheme 1) for delivery and transfection of 
plasmid DNA with 92% efficiency, which surpasses that of 
commercial transfection agents, lipofectamine 2000 (Lipo) 
and polyethylenimine (PEI). Except for simultaneous 
imaging and highly efficient transfection of plasmid DNA,  
in this work, we show that the PFP can also be used for ef-
ficient MDR1-targeted siRNA delivery in doxorubi-
cin-resistant MCF7/ADR cells. The results showed that we 
can efficiently achieve the reversal of drug resistance and 
enhance the drug sensitivity with PFP as siRNA transfection 
agent. 
1  Experimental 
1.1  Materials and measurements 
The PFP was synthesized by our previous method [23]. The 
water was purified using a Millipore filtration system. Me-
thylthiazolyldiphenyl-tetrazolium bromide (MTT) was ob-
tained from Xinjingke Biotechnology Co., Ltd (Beijing, 
China). Goldview DNA dye was purchased from Beijing 
SBS Genetech Co. Ltd (Beijing, China). LipofectamineTM 
2000 was purchased from Invitrogen (Carlsbad, USA). 
TRIzol reagent and DEPC (diethylprocarbonate) water were 
purchased from Beyotime Institute of Biotechnology 
(Shanghai, China). MCF7/ADR cells were purchased from 
KeyGEN Biotech (Nanjing, China). Zeta potentials and size 
analysis were measured on a Nano ZS (ZEN3600) system. 
PCR was conducted on a Bio-Rad Mycycler Thermocycler. 
The image of the gel was taken by a Bio-Rad Molecular 
Imager ChemiDox XRS system. The absorbance for MTT 
analysis was recorded on a microplate reader (BIO-TEK 
Synergy HT, USA) at a wavelength of 520 nm. 
1.2  siRNA and cells  
The siRNA were manufactured by Shanghai GeneChem Co., 
Ltd. and designed to target the human MDR1 mRNA [24] at  
 
 
Scheme 1  Chemical structure of cationic dendritic polyfluorene (PFP). 
the level of the region 88–108 nt relative to the start codon 
(sense strand, 5′-GAAACCAACUGUCAGUGUATT-3′, 
antisense strand, 5′-UACACUGACAGUUGGUUUCTT). 
The lyophilized siRNA were resuspended in 250 L Gene- 
Chem 1 universal buffer to give a 20 mol/L stock solu-
tion. siRNA solutions were heated to 90°C for 2 min and 
then cooled down to room temperature, and stored under 
4°C for further use. MCF7/ADR cells were grown in RPMI 
1640 medium supplemented with 10% FBS, 50 U/mL peni-
cillin, 50 mg/mL streptomycin in a 5% CO2 atmosphere. In 
order to maintain the MDR phenotype, cell culture medium 
for the P-gp expressing MCF7/ADR cell line was supple-
mented with 1.0 g/mL doxorubicin. MCF7/ADR cells 
were incubated in a doxorubicin-free medium for over 2 
weeks before use for experimentation. All of cell lines were 
discarded after 3 months and new lines obtained from fro-
zen stocks. 
1.3  Against nuclease degradation experiment 
Protection of siRNA against nuclease degradation by PFP 
was studied by gel electrophoresis assay. PFP/siRNA com-
plex was incubated in 10% FBS at 37°C for 6 h. After 6 h 
incubation, 10  loading buffer was added to the samples 
and loaded onto the gel for electrophoresis assay. 
1.4  siRNA transfection 
MCF7/ADR cells (3105/well) were plated in six-well 
plates 24 h prior to the experiment. The 12.5 L (20 mol/L) 
siRNA was diluted to 250 L with serum-free medium, and 
2.5 L of PFP (1.0 mmol/L) was also diluted with 250 L 
serum-free media, then the diluted 250 L PFP was added 
to the 250 L diluted siRNA solution, mix gently and incu-
bate for 15–20 min at room temperature. The 500 μL of 
complexes were then added to a well containing cells and 
700 μL serum-free medium, mixing gently by rocking the 
plate back and forth. The 24 h after transfection, fresh sup-
plemented RPMI 1640 (1.0 mL) without penicillin and 
streptomycin was added to the well. The 48 h after initial 
transfection, the medium was replaced with fresh supple-
mented RPMI 1640. The 72 h after initial transfection, the 
medium was removed and the cells were washed with 
phosphate buffered saline (PBS, pH 7.4) three times for 
RNA interference analysis. 
1.5  Reverse transcription-PCR 
After transfection for 72 h, total cellular RNA was extracted 
from cells with TRIzol reagent and quantified by UV ab-
sorbance spectroscopy. The reverse transcription reaction 
was performed using the Quant First Strand cDNA Synthe-
sis Kit (Tiangen Biotech) in a final volume of 20 μL con-
taining 2 μg total RNA. After incubation at 37°C for 60 min, 
the reverse transcription reaction was terminated. The newly 
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synthesized cDNA was amplified by PCR. The 25 μL reac-
tion mixture contained 1 μL cDNA as template, Primers 
used for MDR1 amplification were: 5′-CCCATCA- 
TTGCAA-3′ (sense) and 5′-GTTCAAACTTCTGCTCCT- 
GA-3′ (reverse). Primers for β-actin amplification were:  
5′-ACCAACTGGGACGACATGGA-3′ (sense) and 5′- 
CTCCTTAATGTCACGCACGA-3′ (reverse). Amplifica-
tion cycles were: 95°C for 4 min, the 30 cycles at 95°C for 
30 s, 55°C for 30 s, 72°C for 2 min; followed by 72°C for  
5 min. Amplification products were separated on 2% aga-
rose gel stained with Goldview DNA dye (SBS Genetech). 
The fluorescence intensity of β-actin fragments served as 
the criteria for the MDR1 fragments. 
1.6  Rhodamine 123 efflux assay 
After transfection for 72 h, all cells were trypsinized and 
resuspended in 1 mL fresh growth medium (RPMI 1640 + 
10% FBS), and incubated for 30 min in 5% CO2 at 37°C. 
Rhodamine 123 (Rho-123, final concentration: 1.0 mol/L) 
was added to the cells for incubating another 1 h in the same 
solution. The medium containing Rho-123 was removed 
and the cells were washed with cold phosphate buffered 
saline (PBS, pH 7.4) three times for flow analysis. Fluores-
cence of Rho-123 was collected through a 530/30 nm 
bandpass on a FACSCalibur flow cytometer. After gating 
for live cells, 30000 cells were recorded for each sample 
and processed by Cell Quest software. 
1.7  Chemosensitivity to doxorubicin 
MCF7/ADR cells (8104/well) were plated in 24-well plates 
for siRNA interference. After transfection for 72 h, the me-
dia was replaced with fresh supplemented RPMI 1640 (500 
μL) containing doxorubicin (263 μmol/L). After incubation 
at 37°C in 5% CO2 for 24 h, the medium was poured out 
and the cells were then treated with 500 L of MTT (3 
mg/mL in PBS) and incubated for another 4 h. Then the 
medium was removed, the cells were lysed by adding 600 
L of DMSO, and the absorbance of the purple formazan 
was recorded at 520 nm using a BIO-TEK plate reader. 
2  Results and discussion 
Based on its nucleic acid delivery vector capabilities, PFP 
was specifically used for drug resistance regulation through 
RNA interference. Our previous results demonstrate that the 
PFP exhibits lower cytotoxicity on Dox-resistant human 
breast adenocarcinoma (MCF7/ADR) cells. Although the 
cell viability decreases after 24 h incubation upon increas-
ing concentration of PFP (0–10 mol/L), the viability is still 
larger than 70%. To study the PFP for siRNA delivery and 
transfection, the siRNA that can down-regulate Dox re-
sistance in MCF7 cells was used in our experiment. Firstly, 
we examined whether PFP could protect siRNA against 
enzyme degradation. As shown in Figure 1, similar results 
were obtained as with pDNA, in that siRNA forms tight 
complexes with PFP to resist enzyme degradation. The dy-
namic light scattering (DLS) and zeta potential experiments 
show that the average hydrodynamic diameter of the 
PFP/siRNA complex is 865 nm and that the  potential is 
+18 mV, which are favorable for delivery of siRNA into the 
cells. 
-actin is a globular protein found in all eukaryotic cells, 
which is always used as an internal control for gene express 
[25]. cDNA is a complementary DNA of mRNA from re-
verse transcriptional mRNA template, which can reflect the 
quantitative level of mRNA. As shown in Figure 2, after 
transfection, the level of MDR1 mRNA has been signifi-
cantly reduced by using PFP as the vector in comparison to 
-actin control. This result suggests that PFP can function 
as an efficient siRNA delivery vehicle for gene based drug 
resistance regulation. It is noted that there is no band at-
tributed to MDR1 and -actin appearing on the agarose gel 
when using Lipo as the vector, which indicates that the tox-
icity of Lipo is limited for siRNA interference to MCF7/ 
ADR cells. 
The overexpression of MDR1 gene and its product, P- 
glycoprotein (P-gp), is a particularly significant mechanism 
for drug resistance. P-gp is a 170 kDa transmembrane 
phosphoglycoprotein that acts as an energy-dependent drug 
efflux pump capable of extruding various chemotherapeutic 
drugs such as doxorubicin (Dox) from cell cytoplasm to 
outside of plasma membrane [26], leading to reduced intra-
cellular effective drug concentration and augmenting cell  
 
 
Figure 1  Protection of siRNA from nuclease degradation. Lane 1: 20 bp 
marker; lane 2: naked siRNA; lane 3: naked siRNA with FBS; lane 4: PFP/ 
siRNA; lane 5: PFP/siRNA digested with FBS. 
 
Figure 2  The gel result of cDNA from MDR1 mRNA by siRNA inter-
ference with PFP and Lipo 2000 as transfection agents. -actin was used as 
an internal control. 
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Figure 3  (a)–(c) Rho-123 efflux assays for evaluating the activity of P-gp. FACS histograms of MCF7/ADR cells without any treatment (control) or treat-
ed with 1 mol/L Rho-123 for 1 h. (d) MCF7/ADR cell viability in the presence of Dox before and after treatment with PFP/siRNA, and that of treatment 
only with PFP/siRNA as control.
survival against anticancer drugs. Rhodamine 123 (Rho- 
123), a fluorescent substrate of P-gp, has been widely cho-
sen to evaluate the drug efflux ability of P-gp [27]. Figure 
3(a)–(c) shows flow cytometry histograms of gated living 
cells with distribution of Rho-123 fluorescence, in which 
marker M1 was placed around the peak of cell autofluores-
cence (MCF7/ADR cells without Rho-123) as control, and 
marker M2 was placed to the right of M1 to designate the 
percentages of cells with the fluorescence of Rho-123. In 
the absence of siRNA treatment, there was some Rho-123 
accumulating in cells with M2 of 86.00%. After treatment 
with PFP/siRNA, an increase in Rho-123 accumulation was 
observed with an M2 value of 93.19%. The enhancement of 
chemosensitivity to Dox was expressed as the decrease of 
the survival rate after incubation with Dox of siRNA-treated 
cells compared with siRNA-untreated control cells. As 
shown in Figure 3(d), after treatment with PFP/siRNA, the 
cell viability was decreased to 33% in the presence of Dox 
comparing to that without treatment with PFP/siRNA (47%). 
All these results demonstrate that PFP is good siRNA trans-
fection agent, and can efficiently achieve the reversal of 
drug resistance and enhance the drug sensitivity. 
3  Conclusions 
In summary, the cationic dendritic conjugated polymer PFP 
can act as efficient siRNA delivery vector by facilitating the 
nucleic acid binding, encapsulation and efficient cellular 
uptake. PFP can effectively protect siRNA against nuclease 
degradation, which is necessary for gene carriers. PFP can 
be used for multidrug resistance gene-targeted siRNA de-
livery in doxorubicin (Dox)-resistant human breast cancer 
cells (MCF7) cells. As a siRNA transfection agent, PFP can 
efficiently achieve the reversal of drug resistance and en-
hance the drug sensitivity. To the best of our knowledge, 
this is the first reported conjugated polymer that can be em-
ployed for gene-based drug resistance regulation. These 
new features and capabilities represent an innovative step 
toward synthetic polycationic vectors for therapeutic appli-
cations. 
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